COVID-19 and the gut microbiome: More than a gut feeling

mSystems

Volumn 5, Issue 4, 2020, Pages

  van der Lelie, Daniel ^a   Taghavi, Safiyh ^a  

^a Gusto Global LLC   (United States)

Author keywords

COVID 19; Gut microbiome

Indexed keywords

ALPHA INTERFERON; ANGIOTENSIN CONVERTING ENZYME 2; CYTOKINE; INTERLEUKIN 6 RECEPTOR ANTIBODY; MONOCLONAL ANTIBODY; RECEPTOR ANTIBODY; REMDESIVIR; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANTIVIRAL ACTIVITY; ARTICLE; CORONAVIRUS DISEASE 2019; DISEASE EXACERBATION; DISEASE SEVERITY; DYSBIOSIS; HUMAN; INFECTION SENSITIVITY; INTESTINE FLORA; KLEBSIELLA; LACTOBACILLUS; NONHUMAN; RESPIRATORY VIRUS; RUMINOCOCCUS; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; STREPTOCOCCUS; VIRAL CLEARANCE; VIRAL RESPIRATORY TRACT INFECTION; VIRUS REPLICATION;

EID: 85089247737     PISSN: None     EISSN: 23795077     Source Type: Journal    
DOI: 10.1128/mSystems.00453-20     Document Type: Article

References (22)

1. Moore JB, June CH. 2020. Cytokine release syndrome in severe COVID-19. Lessons from arthritis and cell therapy in cancer patients point to therapy for severe disease. Science 368:473-474. https://doi.org/10.1126/science.abb8925.
2. Jones VG, Mills M, Suarez D, Hogan CA, Yeh D, Segal JB, Nguyen EL, Barsh GR, Maskatia S, Mathew R. 2020. COVID-19 and Kawasaki disease: novel virus and novel case. Hosp Pediatr 10:537-540. https://doi.org/10.1542/hpeds.2020-0123.
3. Gordon CJ, Tchesnokov EP, Feng JY, Porter P, Götte M. 2020. The antiviral compound remdesivir potently inhibits RNA-dependent RNA polymerase from Middle East respiratory syndrome coronavirus. J Biol Chem 295:4773- 4779. https://doi.org/10.1074/jbc.AC120.013056.
4. Casadevall A, Pirofski L-A. 2020. The convalescent sera option for containing COVID-19. J Clin Invest 130:1545-1548. https://doi.org/10.1172/ JCI138003.
5. Belhadi D, Peiffer-Smadja N, Yazdanpanah Y, Mentré F, Laouénan C. 2020. A brief review of antiviral drugs evaluated in registered clinical trials for COVID-19. medRxiv https://doi.org/10.1101/2020.03.18.20038190.
6. Martinez MA. 2020. Compounds with therapeutic potential against novel respiratory 2019 coronavirus. Antimicrob Agents Chemother 64:e00399-20. https://doi.org/10.1128/AAC.00399-20.
7. Mantlo E, Bukreyeva N, Maruyama J, Paessler S, Huang C. 2020. Antiviral activities of type I interferons to SARS-CoV-2 infection. Antiviral Res 179:104811-104814. https://doi.org/10.1016/j.antiviral.2020.104811.
8. Bradley KC, Finsterbusch K, Schnepf D, Crotta S, Llorian M, Davidson S, Fuchs SY, Staeheli P, Wack A. 2019. Microbiota-driven tonic interferon signals in lung stromal cells protect from influenza virus infection. Cell Rep 28:245-256. https://doi.org/10.1016/j.celrep.2019.05.105.
9. Steed AL, Christophi GP, Kaiko GE, Sun L, Goodwin VM, Jain U, Esaulova E, Artyomov MN, Morales DJ, Holtzman MJ, Boon ACM, Lenschow DJ, Stappenbeck TS. 2017. The microbial metabolite desaminotyrosine protects from influenza through type I interferon. Science 357:498-502. https://doi.org/10.1126/science.aam5336.
10. Pan L, Mu M, Yang P, Sun Y, Wang R, Yan J, Li P, Hu B, Wang J, Hu C, Jin Y, Niu X, Ping R, Du Y, Li T, Xu G, Hu Q, Tu L. 2020. Clinical characteristics of COVID-19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional, multicenter study. Am J Gastroenterol 115: 766-773. https://doi.org/10.14309/ajg.0000000000000620.
11. Deriu E, Boxx GM, He X, Pan C, Benavidez SD, Cen L, Rozengurt N, Shi W, Cheng G. 2016. Influenza virus affects intestinal microbiota and secondary Salmonella infection in the gut through Type I interferons. PLoS Pathog 12:e1005572. https://doi.org/10.1371/journal.ppat.1005572.
12. Wasimuddin, Corman VM, Ganzhorn JU, Rakotondranary J, Ratovonamana YR, Drosten C, Sommer S. 2019. Adenovirus infection is associated with altered gut microbial communities in a non-human primate. Sci Rep 9:e13410. https://doi.org/10.1038/s41598-019-49829-z.
13. Li N, Ma W-T, Pang M, Fan Q-L, Hua J-L. 2019. The commensal microbiota and viral infection: a comprehensive review. Front Immunol 10:e1551. https://doi.org/10.3389/fimmu.2019.01551.
14. Hashimoto T, Perlot T, Rehman A, Trichereau J, Ishiguro H, Paolino M, Sigl V, Hanada T, Hanada R, Lipinski S, Wild B, Camargo SMR, Singer D, Richter A, Kuba K, Fukamizu A, Schreiber S, Clevers H, Verrey F, Rosenstiel P, Penninger JM. 2012. ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation. Nature 487:477-481. https://doi.org/10.1038/nature11228.
15. Chan J-W, Kok K-H, Zhu Z, Chu H, To KK-W, Yuan S, Yuen K-Y. 2020. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 9:221-236. https://doi.org/10.1080/22221751.2020.1719902.
16. Wang J, Zhao S, Liu M, Zhao Z, Xu Y, Wang P, Lin M, Xu Y, Huang B, Zuo X, Chen Z, Bai F, Cui J, Lew AM, Zhao J, Zhang Y, Luo H-B, Zhang Y. 2020. ACE2 expression by colonic epithelial cells is associated with viral infection, immunity and energy metabolism. medRxiv https://doi.org/10.1101/2020.02.05.20020545.
17. Zhou J, Li C, Zhao G, Chu H, Wang D, Yan HH-N, Poon VK-M, Wen L, Wong BH-Y, Zhao X, Chiu MC, Yang D, Wang Y, Au-Yeung RKH, Chan IH-Y, Sun S, Chan JK-W, To KK-W, Memish ZA, Corman VM, Drosten C, Hung IF-N, Zhou Y, Leung SY, Yuen K-Y. 2017. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci Adv 3:eaao4966. https://doi.org/10.1126/sciadv.aao4966.
18. Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H. 2020. Evidence for gastrointestinal infection of SARS-CoV-2. Gastroenterology 158: 1831-1833. https://doi.org/10.1053/j.gastro.2020.02.055.
19. Han C, Duan C, Zhang S, Spiegel B, Shi H, Wang W, Zhang L, Lin R, Liu J, Ding Z, Hou X. 2020. Digestive symptoms in COVID-19 patients with mild disease severity: clinical presentation, stool viral RNA testing, and outcomes. Am J Gastroenterol 115:916-923. https://doi.org/10.14309/ajg.0000000000000664.
20. Vandeputte D, Falony G, Vieira-Silva S, Tito RY, Joossens M, Raes J. 2016. Stool consistency is strongly associated with gut microbiota richness and composition, enterotypes and bacterial growth rates. Gut 65:57-62. https://doi.org/10.1136/gutjnl-2015-309618.
21. Gou W, Fu Y, Yue L, Chen G-D, Cai X, Shuai M, Xu F, Chen H, Zhu Y, Xiao M-L, Jiang Z, Miao Z, Xiao C, Shen B, Wu X, Zhao H, Ling W, Wang J, Chen Y-M, Guo T, Zheng J-S. 2020. Gut microbiota may underlie the predisposition of healthy individuals to COVID-19. medRxiv https://doi.org/10.1101/2020.04.22.20076091.
22. Esposito S, Polinori I, Rigante D. 2019. The gut microbiota-host partnership as a potential driver of Kawasaki syndrome. Front Pediatr 7:124. https://doi.org/10.3389/fped.2019.00124.